Plasma Renin Activity: When to Order This Test and What Your Results Mean

What Plasma Renin Activity Actually Measures

Plasma renin activity tells you how fast renin, an enzyme released by your kidneys, is cleaving angiotensinogen into angiotensin I per unit of time. The result is expressed in nanograms of angiotensin I produced per milliliter of plasma per hour (ng/mL/hr). This is different from a direct renin concentration assay, which counts renin molecules rather than measuring enzymatic speed.

The distinction matters clinically. Direct renin concentration and PRA generally track together, but the Endocrine Society's 2016 clinical practice guideline on primary aldosteronism specifies that the aldosterone-to-renin ratio should be calculated using the same renin assay type consistently within a laboratory, because ARR cutoffs differ depending on whether you used PRA or direct renin concentration. Many U.S. Labs still report PRA; many European and Australian labs have shifted to direct renin concentration. Knowing which one your lab runs prevents misinterpretation.

How the Renin-Angiotensin-Aldosterone System Works in Women

Renin converts angiotensinogen (made mainly in the liver) to angiotensin I. Angiotensin-converting enzyme then converts angiotensin I to angiotensin II, which raises blood pressure directly and stimulates the adrenal cortex to secrete aldosterone. Aldosterone tells the kidneys to retain sodium and excrete potassium.

For women, estrogen adds a layer of complexity. Estrogen stimulates hepatic angiotensinogen synthesis, raising the substrate available for renin to act on. This means that with the same renin activity, a woman on estrogen-containing oral contraceptives (OCPs) or in the late follicular phase may generate more angiotensin II than a postmenopausal woman off hormone therapy. A 2019 review in the Journal of the American Heart Association confirmed that estrogen-driven angiotensinogen elevation is a key mechanism behind OCP-associated hypertension in susceptible women.

Why Enzymatic Activity Is Not the Same as Renin Level

A woman on a high-sodium diet may have a low PRA because sodium loading suppresses renin release, even if her renin concentration is biochemically detectable. Conversely, a woman who has been vomiting, is on a loop diuretic, or has renal artery stenosis will have high PRA because her kidneys sense reduced perfusion and pump out renin. The test is measuring the system's activity level, not simply renin abundance.

When Your Clinician Should Order a PRA Test

The test is ordered in four main clinical scenarios. It is not a routine screening lab and is not included in standard metabolic panels.

Scenario 1: Screening for Primary Aldosteronism

Primary aldosteronism (PA) is the most common cause of secondary hypertension, affecting an estimated 5 to 10 percent of all hypertensive patients and up to 20 percent of those with treatment-resistant hypertension. In PA, an adrenal adenoma or bilateral adrenal hyperplasia autonomously secretes aldosterone, which suppresses renin through negative feedback. The result is a low PRA paired with high aldosterone.

The Endocrine Society recommends calculating the ARR as the first-line screening test. An ARR above approximately 30 (using aldosterone in ng/dL and PRA in ng/mL/hr) is considered a positive screen requiring confirmatory testing. Women are disproportionately represented in PA case series; one meta-analysis in the Journal of Clinical Endocrinology and Metabolism found that bilateral adrenal hyperplasia is more common in women than men with PA, which has implications for surgical versus medical management decisions.

Scenario 2: Investigating Secondary Hypertension

The 2018 ACC/AHA hypertension guideline recommends evaluating for secondary causes when hypertension appears before age 30, when it is refractory to three medications, or when it is accompanied by hypokalemia, adrenal incidentaloma, or obstructive sleep apnea. For women specifically, hypertension onset in perimenopause, hypertension during OCP use, or postpartum hypertension that persists are additional signals to investigate secondary causes including PA.

Renal artery stenosis, another cause of secondary hypertension, produces a high PRA because the kidney past the stenosis perceives reduced perfusion. In fibromuscular dysplasia (FMD), a non-atherosclerotic arterial disease that disproportionately affects women, with a reported female-to-male ratio of approximately 9:1, renal artery involvement commonly causes high-PRA secondary hypertension. FMD is a reason to check PRA in a young woman with new hypertension who has no obesity, no family history, and no other obvious risk factors.

Scenario 3: Unexplained Hypokalemia

A serum potassium below 3.5 mEq/L without an obvious cause (vomiting, diarrhea, diuretics) should prompt paired aldosterone and PRA measurement. Aldosteronism drives urinary potassium wasting; the PRA helps distinguish whether excess aldosterone is autonomous (PA: low PRA) or appropriately reactive (secondary aldosteronism from volume depletion: high PRA).

Scenario 4: Monitoring Antihypertensive Therapy

Some clinicians use PRA-guided therapy, pairing renin status with drug choice. High-PRA hypertension responds better to ACE inhibitors and ARBs. Low-PRA hypertension tends to respond better to calcium channel blockers and thiazide diuretics. A 2021 paper in Hypertension explored renin-guided therapy, though the authors noted that sex-disaggregated outcome data remain limited, and most evidence is extrapolated from predominantly male or mixed-sex cohorts.

Normal Plasma Renin Activity Range

Reference ranges differ by body position, sodium intake, time of day, and the specific assay platform. These figures are approximate.

| Condition | Approximate PRA (ng/mL/hr) | |---|---| | Supine, normal sodium diet | 0.5 to 4.0 | | Upright 2 hours, normal sodium diet | 1.0 to 4.3 | | Low-sodium diet (stimulated) | Up to 10 | | First trimester pregnancy | 2 to 6 | | Third trimester pregnancy | 4 to 12 | | Primary aldosteronism (typical) | <1.0, often <0.5 |

Always interpret your result against your specific laboratory's reference interval, not a generic table. Labs calibrate their assays differently, and a value of 0.6 ng/mL/hr might be flagged low at one institution but sit within normal at another.

How Sex Hormones Shift the Reference Range

Oral contraceptives containing ethinyl estradiol raise angiotensinogen and suppress PRA through the negative feedback loop described above. Studies comparing PRA in OCP users versus non-users have documented PRA suppression of 30 to 50 percent in OCP users, which can produce an ARR that appears falsely elevated. If your clinician is screening for PA and you take combined hormonal contraceptives, the test ideally should be done after a 4-week washout or interpreted with the OCP effect in mind.

Progestin-only contraceptives have variable effects depending on the progestin's antimineralocorticoid activity. Drospirenone, found in some combined pills and in the progestin-only pill Slynd, has antimineralocorticoid properties that can modestly raise PRA. This is relevant if you are being screened for aldosteronism while on a drospirenone-containing pill.

What a High Plasma Renin Activity Means

A high PRA means your kidneys are perceiving reduced perfusion, volume depletion, or are reacting to a signal that is driving renin release. The most common causes include:

• Renovascular hypertension (renal artery stenosis, FMD)
• Volume depletion from diuretic use, vomiting, diarrhea, or low sodium intake
• Addison's disease (primary adrenal insufficiency), where loss of aldosterone causes sodium wasting and reflex high renin
• Renin-secreting tumors (rare)
• Malignant hypertension
• Bartter syndrome and Gitelman syndrome (rare tubulopathies more frequently diagnosed in younger women who present with hypokalemia and normal blood pressure)

High PRA in the context of low or normal aldosterone points toward volume depletion or adrenal insufficiency rather than autonomous aldosterone excess.

High PRA in Pregnancy

Pregnancy normally raises PRA significantly. By the end of the third trimester, PRA may be two to three times the non-pregnant upper limit. This physiological rise is driven by estrogen-stimulated angiotensinogen, progesterone-mediated sodium natriuresis, and reduced vascular resistance. Interpreting a PRA result against non-pregnant reference ranges during pregnancy will therefore produce false positives for high renin conditions. Use trimester-specific ranges and interpret alongside a maternal-fetal medicine or hypertension specialist.

Preeclampsia presents a paradox: despite high blood pressure, PRA is often paradoxically low relative to the degree of vasoconstriction, because placental and endothelial dysfunction alters the normal gestational RAAS response. A PRA that fails to rise appropriately across pregnancy may be an early marker of disordered placentation, though this is not yet a clinical screening tool.

What a Low Plasma Renin Activity Means

A low PRA (typically <0.5 ng/mL/hr in an upright, ambulatory, non-pregnant woman on a normal-sodium diet) narrows the differential considerably.

The dominant concern is primary aldosteronism. The adrenal gland is producing aldosterone without needing renin's permission, and the resulting sodium and water retention suppresses renin release. Other causes of low PRA include:

• Primary aldosteronism (adrenal adenoma or bilateral hyperplasia)
• Cushing's syndrome (cortisol has some mineralocorticoid activity)
• Apparent mineralocorticoid excess syndromes
• Licorice ingestion (glycyrrhizin inhibits 11-beta-hydroxysteroid dehydrogenase)
• Older age (renin levels decline physiologically with age)
• High dietary sodium intake

Low PRA and PCOS

Women with polycystic ovary syndrome deserve specific attention here. PCOS is associated with elevated aldosterone and blunted PRA in a subset of patients, a pattern that mirrors subclinical primary aldosteronism. A 2020 study in the Journal of Clinical Endocrinology and Metabolism found that women with PCOS had significantly higher aldosterone-to-renin ratios than age- and BMI-matched controls, suggesting that aldosterone excess may contribute to the cardiometabolic risk profile seen in PCOS beyond what insulin resistance alone explains. This is a clinically underappreciated connection. If you have PCOS with hypertension or hypokalemia, ask your clinician whether an ARR has been checked.

Low PRA in Perimenopause and Postmenopause

Postmenopausal women have lower renin levels on average compared with premenopausal women, partly because estrogen-driven angiotensinogen synthesis declines after menopause. This means the ARR cutoffs validated in largely premenopausal or mixed-sex populations may not translate perfectly to postmenopausal women. The Endocrine Society 2016 PA guideline acknowledges that age affects renin and aldosterone levels but does not provide sex- and age-stratified ARR cutoffs, a recognized evidence gap. Postmenopausal women on systemic hormone therapy with estrogen may have a partially restored angiotensinogen level, shifting their PRA closer to premenopausal values.

How to Prepare for a PRA Test

Preparation matters more for this test than for most routine labs. Errors in collection or preparation are a leading cause of unreliable results.

Dietary and Medication Considerations

• Sodium intake: Maintain your usual diet for at least 2 weeks before testing. A sudden switch to low sodium falsely raises PRA; a sodium load suppresses it.
• Potassium: Correct hypokalemia before testing. Low potassium itself suppresses aldosterone secretion and can cause false-negative PA screening.
• Antihypertensives: Many medications interfere. ACE inhibitors and ARBs raise PRA by blocking the angiotensin II feedback. Mineralocorticoid receptor antagonists (spironolactone, eplerenone) raise PRA substantially. Diuretics raise PRA. Beta-blockers suppress PRA. The Endocrine Society guideline recommends a 4-week washout from interfering medications before definitive ARR testing, substituting non-interfering agents such as verapamil SR and hydralazine if blood pressure control is needed.
• OCPs and hormone therapy: As described above, discuss with your clinician whether a washout period is needed.

Specimen Handling

Blood must be drawn into a pre-chilled EDTA tube and transported immediately on ice to the laboratory. Room-temperature storage activates or degrades renin enzymatically, shifting the result. This is a pre-analytical variable that patients cannot control but should know about when results look unexpectedly abnormal.

Time of Day and Position

Renin follows a circadian rhythm and responds to posture. Most protocols call for a morning draw after at least 2 hours of upright posture (sitting or standing), which provides a stimulated rather than suppressed baseline. Some protocols require a separate draw after 1 hour of supine rest to assess the posture-related renin increment; this is used in some PA subtype evaluation algorithms.

Pregnancy and Lactation Considerations

This section applies because hypertension disorders affect up to 10 to 15 percent of pregnancies in the United States, and distinguishing primary from secondary hypertension before or during pregnancy has direct management implications.

Testing in Pregnancy

PRA is not routinely ordered during pregnancy. If a woman is known to have PA before conception, or if PA is suspected during pregnancy (unexplained hypokalemia, difficult-to-control hypertension, adrenal mass), testing can be done but requires trimester-specific interpretation. A maternal-fetal medicine specialist should be involved. ACOG Practice Bulletin 222 on gestational hypertension and preeclampsia does not specifically address PA screening during pregnancy, reflecting the evidence gap for this overlap population.

Managing PA During Pregnancy

Spironolactone, the first-line medical treatment for PA, is teratogenic and contraindicated in pregnancy because it crosses the placenta and has antiandrogenic effects that may feminize a male fetus. Women of reproductive age with PA who are managed with spironolactone need reliable contraception. If pregnancy occurs, spironolactone must be stopped immediately.

Eplerenone has less antiandrogenic activity and limited safety data in pregnancy; it is generally avoided. Amiloride, a potassium-sparing diuretic, has been used in case reports of PA in pregnancy as a safer alternative, though it is not FDA-approved for this indication and should be managed by a specialist.

For women who want to conceive and have a unilateral adrenal adenoma causing PA, adrenalectomy before pregnancy is preferable to managing medically throughout gestation.

Lactation

Spironolactone does transfer into breast milk, though the relative infant dose is estimated at under 5 percent, which is generally below the 10 percent threshold used to flag concern. Most references classify spironolactone as probably compatible with breastfeeding, but data are limited. Canrenone, its active metabolite, is the form that transfers. Women who need mineralocorticoid receptor antagonist therapy postpartum should discuss the benefit-risk balance with their clinician.

How to Lower Plasma Renin Activity

Lowering PRA is rarely the goal in itself; the clinical objective is usually to identify and treat the condition driving an abnormally high PRA. Some modifiable factors reduce PRA:

• Sodium repletion: Expanding intravascular volume is the fastest physiological way to reduce renin release. This is relevant in volume depletion states.
• Treating renovascular disease: Renal artery revascularization (angioplasty, stenting) reduces the ischemic kidney's renin secretion and can normalize PRA in FMD-related hypertension.
• ACE inhibitors and ARBs: These drugs reduce angiotensin II feedback, which actually raises PRA. They are the wrong choice for mechanistically lowering PRA, even though they lower blood pressure.
• Beta-blockers: Suppress renin release from the juxtaglomerular apparatus by blocking beta-1 adrenergic stimulation. This is one mechanism by which beta-blockers lower blood pressure in high-renin hypertension.
• Calcium channel blockers: Have a modest PRA-lowering effect.

How to Raise Plasma Renin Activity

Again, raising PRA is rarely the direct treatment goal. A low PRA in the context of PA is corrected by treating the underlying cause. However, some approaches raise PRA as a testing maneuver or as a therapeutic side effect:

• Sodium restriction: A low-sodium diet stimulates renin release; this is the basis of stimulated renin testing protocols.
• Upright posture: Two hours of standing or walking raises PRA compared with a supine draw.
• Diuretics: Furosemide and thiazides cause volume depletion and raise PRA, which is why they must be stopped before diagnostic testing.
• ACE inhibitors and ARBs: Block angiotensin II feedback, raising PRA.
• Treating PA surgically or with mineralocorticoid receptor antagonists: After adrenalectomy for a unilateral aldosterone-producing adenoma, aldosterone falls and renin recovers over weeks to months as the suppression is lifted.

Who This Test Is Right For and Who Can Wait

Strong Indications for PRA Testing

• You have hypertension that started before age 30 with no clear lifestyle cause
• Your blood pressure requires three or more medications to control
• You have unexplained serum potassium below 3.5 mEq/L
• You have an adrenal incidentaloma found on imaging
• You have PCOS with hypertension or hypokalemia
• You are perimenopausal or postmenopausal with new-onset or worsening hypertension that was not explained by a recent evaluation
• You have hypertension and symptoms suggesting FMD (young woman, bruit over kidney area, pulsatile tinnitus)
• Your clinician wants to guide antihypertensive drug selection using renin status

Situations Where PRA Testing Can Wait or Requires Modification

• You are currently pregnant: defer routine PA screening unless clinically urgent, and use trimester-specific ranges
• You are on OCPs: consider a 4-week washout before definitive ARR testing, or at minimum note OCP use in the interpretation
• You recently changed your sodium intake or started a diuretic: retest after diet stabilization and medication washout
• You have straightforward hypertension well-controlled on one medication with no hypokalemia or other red flags: routine PRA testing adds little in this scenario

A Candid Note on Evidence Gaps for Women

Women have been systematically underrepresented in the clinical trials and cohort studies that defined PRA reference ranges and ARR cutoffs. The Endocrine Society's 2016 PA guideline was developed from evidence that largely did not stratify results by sex, menstrual phase, or menopausal status. The practical consequence is that clinicians apply cutoffs derived from mixed or male-predominant populations to women whose hormonal milieu genuinely shifts renin and aldosterone.

"We currently lack sex-specific ARR thresholds that account for the menstrual cycle, exogenous hormone use, and menopausal status," says Elena Vasquez, MD, a reproductive endocrinologist and member of the WomanRx clinical editorial board. "A woman on a combined oral contraceptive with a borderline ARR needs her result interpreted very differently from a postmenopausal woman off hormone therapy with the same number. Treating these as equivalent is a diagnostic error."

This gap does not mean PRA testing is unreliable in women. It means the test must be interpreted with explicit attention to hormonal context, and any borderline ARR in a woman on exogenous estrogen warrants a repeat test after washout before a diagnosis of PA is made or excluded.